Shifting Gears: The Future of Polymyxin Antibiotics

Shifting Gears: The Future of Polymyxin Antibiotics

The manuscripts contained in this special edition of Antibiotics represent a current review of the polymyxins as well as highlights from the 3rd International Polymyxin Conference, which was held in Madrid, Spain, 25 to 26 April 2018. The role of the polymyxin antibiotics has evolved over time based...

Full description

Bibliographic Details
Main Authors:	Justin R. Lenhard, Zackery P. Bulman, Brian T. Tsuji, Keith S. Kaye
Format:	Article
Language:	English
Published:	MDPI AG 2019-04-01
Series:	Antibiotics
Subjects:	polymyxins <i>Acinetobacter baumannii</i> <i>Klebsiella pneumoniae</i> <i>Pseudomonas aeruginosa</i> carbapenem resistance β-lactamase inhibitors avibactam ceftolozane cefiderocol inhaled antibiotics
Online Access:	https://www.mdpi.com/2079-6382/8/2/42

Similar Items

Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant <i>Acinetobacter baumannii</i> with Polymyxin-Based Combinations
by: Marisol Wences, et al.
Published: (2022-07-01)

Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii-calcoaceticus Complex</i>
by: Rebeca Carvalho Lacerda Garcia, et al.
Published: (2023-08-01)

Intravenous Polymyxin B as Adjunctive Therapy to High-Dose Tigecycline for the Treatment of Nosocomial Pneumonia Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i>: A Propensity Score-Matched Cohort Study
by: Lei Zha, et al.
Published: (2023-01-01)

Guanidinylated Polymyxins as Outer Membrane Permeabilizers Capable of Potentiating Rifampicin, Erythromycin, Ceftazidime and Aztreonam against Gram-Negative Bacteria
by: Danzel Marie Ramirez, et al.
Published: (2022-09-01)

Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?
by: Song Oh, et al.
Published: (2021-05-01)

Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in <i>Acinetobacter baumannii</i>
by: Jacinda C. Abdul-Mutakabbir, et al.
Published: (2024-01-01)

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Aisling R. Caffrey, et al.
Published: (2022-05-01)

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
by: Davide Fiore Bavaro, et al.
Published: (2021-05-01)

Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
by: Helen Giamarellou, et al.
Published: (2022-07-01)

Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution
by: Katerina Tsilipounidaki, et al.
Published: (2022-01-01)

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates
by: Clara Ballesté-Delpierre, et al.
Published: (2022-01-01)

Cefiderocol Treatment for Severe Infections due to Difficult-to-Treat-Resistant Non-Fermentative Gram-Negative Bacilli in ICU Patients: A Case Series and Narrative Literature Review
by: Paul-Henri Wicky, et al.
Published: (2023-06-01)

Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i>: A Multicenter Study in China
by: Xuemei Zhen, et al.
Published: (2020-08-01)

Prevalence and Molecular Characteristics of Polymyxin-Resistant <i>Pseudomonas aeruginosa</i> in a Chinese Tertiary Teaching Hospital
by: Chenlu Xiao, et al.
Published: (2022-06-01)

Novel Antimicrobial Agents for Gram-Negative Pathogens
by: Marios Karvouniaris, et al.
Published: (2023-04-01)

Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence
by: Matthew E. Falagas, et al.
Published: (2021-03-01)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
by: Andrea Marino, et al.
Published: (2022-12-01)

In Vitro Activity of Ceftolozane-Tazobactam against <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa
by: Olga Perovic, et al.
Published: (2023-02-01)

XDR-<i>Pseudomonas aeruginosa</i> Outside the ICU: Is There Still Place for Colistin?
by: Paola Del Giacomo, et al.
Published: (2022-02-01)

Association of <i>bla</i><sub>VIM-2</sub>, <i>bla</i><sub>PDC-35</sub>, <i>bla</i><sub>OXA-10,</sub> <i>bla</i><sub>OXA-488</sub> and <i>bla</i><sub>VEB-9</sub> β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Mazen A. Sid Ahmed, et al.
Published: (2022-01-01)

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
by: Chen J, et al.
Published: (2022-02-01)

Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections
by: Amer El Ghali, et al.
Published: (2024-02-01)

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
by: Alexandre Bleibtreu, et al.
Published: (2021-01-01)

Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences
by: Marianna Criscuolo, et al.
Published: (2020-02-01)

Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Strains-Distribution of the Essential Enzymatic Virulence Factors Genes
by: Tomasz Bogiel, et al.
Published: (2020-12-01)

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant <i>Acinetobacter baumannii</i> (CRAB) Isolates
by: Fernando Pasteran, et al.
Published: (2021-05-01)

In Vitro Activity of Ceftolozane-Tazobactam and Other Antibiotics against <i>Pseudomonas aeruginosa</i> Infection-Isolates from an Academic Medical Center in Thailand
by: Woraphot Tantisiriwat, et al.
Published: (2022-05-01)

Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital
by: C. Weber, et al.
Published: (2022-10-01)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022-12-01)

Combined Resistance to Ceftolozane-Tazobactam and Ceftazidime-Avibactam in Extensively Drug-Resistant (XDR) and Multidrug-Resistant (MDR) <i>Pseudomonas aeruginosa</i>: Resistance Predictors and Impact on Clinical Outcomes Besides Implications for Antimicrobial Stewardship Programs
by: Marianna Meschiari, et al.
Published: (2021-10-01)

Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion
by: Nicola Coppola, et al.
Published: (2022-09-01)

The Iron Content of Human Serum Albumin Modulates the Susceptibility of <i>Acinetobacter baumannii</i> to Cefiderocol
by: Jenny Escalante, et al.
Published: (2023-02-01)

Incidence of metallo-beta-lactamase-producing <i> Pseudomonas aeruginosa</i> in diabetes and cancer patients
by: Varaiya Ami, et al.
Published: (2008-04-01)

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany
by: Beniam Ghebremedhin, et al.
Published: (2021-09-01)

Current State of Knowledge Regarding WHO Critical Priority Pathogens: Mechanisms of Resistance and Proposed Solutions through Candidates Such as Essential Oils
by: Bianca Badescu, et al.
Published: (2022-07-01)

A 2-Year Single-Centre Audit on Antibiotic Resistance of <i>Pseudomonas aeruginosa</i>, <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i> Strains from an Intensive Care Unit and Other Wards in a General Public Hospital in Greece
by: Georgios Feretzakis, et al.
Published: (2019-05-01)

Treatments and Predictors of Mortality for Carbapenem-Resistant Gram-Negative Bacilli Infections in Malaysia: A Retrospective Cohort Study
by: Usman Abubakar, et al.
Published: (2022-12-01)

Long-Term Surveillance of Antibiotic Prescriptions and the Prevalence of Antimicrobial Resistance in Non-Fermenting Gram-Negative Bacilli
by: Chia-Huei Chou, et al.
Published: (2020-03-01)

Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients
by: Christian M. Gill, et al.
Published: (2022-11-01)

Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates
by: Raúl Recio, et al.
Published: (2022-06-01)